AI-generated summary
The authors report a randomised, placebo-controlled, double-blinded trial of 830 nm photobiomodulation in 31 head and neck cancer patients with chronic radiotherapy-induced xerostomia. The active group showed a nearly significant increase in unstimulated salivary flow compared with placebo (p = 0.051), and five patients moved from hyposalivation to normal flow. The authors describe these findings as preliminary and call for larger studies.
- Participants
- 31
- Who or what was studied
- Adults with head and neck cancer in complete remission and chronic xerostomia more than 3 months after radiotherapy
- Wavelengths
- 830 nm
- Limits stated in the abstract
- The authors state the sample was small, the between-group salivary flow difference was not statistically significant, and biochemical and other outcomes were less definitive.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on bmcoralhealth.biomedcentral.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 830 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Placebo-controlled, Trial registration, Near-infrared, Effect size, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.